Genocea Biosciences (LTS:0A51) Days Payable: 0.00 (As of Mar. 2022)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0A51 Genocea Biosciences Inc LTS:0A51
16 GF Score
Price $0.00
View Full Analysis

What is Genocea Biosciences Days Payable?

Genocea Biosciences LTS:0A51 16 Days Payable is 0.00 as of Mar. 2022. GuruFocus rates LTS:0A51 with a GF Score™ of 16/100.

Genocea Biosciences's average Accounts Payable for the three months ended in Mar. 2022 was $0.55 Mil. Genocea Biosciences's Cost of Goods Sold for the three months ended in Mar. 2022 was $0.00 Mil.

The historical rank and industry rank for Genocea Biosciences's Days Payable or its related term are showing as below:

LTS:0A51's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 113.1
* Ranked among companies with meaningful Days Payable only.

Genocea Biosciences's Days Payable stayed the same from Mar. 2021 (0.00) to Mar. 2022 (0.00). stayed the same

Genocea Biosciences Days Payable Historical Data

* Premium members only.

The historical data trend for Genocea Biosciences's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genocea Biosciences Days Payable Chart

Genocea Biosciences Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Days Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Genocea Biosciences Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
Days Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

LTS:0A51 vs FNAM, BXRX, XSNX: Days Payable Comparison

For the Biotechnology subindustry, Genocea Biosciences's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genocea Biosciences Days Payable vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genocea Biosciences's Days Payable distribution charts can be found below:

* The bar in red indicates where Genocea Biosciences's Days Payable falls into.


LTS:0A51
16GF Score
Genocea Biosciences Inc LTS:0A51
Days Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genocea Biosciences Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Genocea Biosciences's Days Payable for the fiscal year that ended in Dec. 2021 is calculated as

Days Payable (A: Dec. 2021 )
=Average Accounts Payable /Cost of Goods Sold*Days in Period
=( (Accounts Payable (A: Dec. 2020 ) + Accounts Payable (A: Dec. 2021 )) / count ) / Cost of Goods Sold (A: Dec. 2021 )*Days in Period
=( (0.534 + 0.5) / 2 ) / 0*365
=0.517 / 0*365
=N/A

Genocea Biosciences's Days Payable for the quarter that ended in Mar. 2022 is calculated as:

Days Payable (Q: Mar. 2022 )
=Average Accounts Payable / Cost of Goods Sold*Days in Period
=( (Accounts Payable (Q: Dec. 2021 ) + Accounts Payable (Q: Mar. 2022 )) / count ) / Cost of Goods Sold (Q: Mar. 2022 )*Days in Period
=( (0.5 + 0.594) / 2 ) / 0*365 / 4
=0.547 / 0*365 / 4
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Days Payable →
What does a Days Payable of 0.00 mean?
Genocea Biosciences (LTS:0A51) has a Days Payable of 0.00 as of Mar. 2022. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Genocea Biosciences and its competitors.
Is Genocea Biosciences' Days Payable too high?
Genocea Biosciences' current Days Payable is 0.00. Overall, Genocea Biosciences has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Genocea Biosciences' Days Payable compare to FNAM and BXRX?
Genocea Biosciences' Days Payable of 0.00 can be compared against companies in the Biotechnology industry. The industry median Days Payable is 113.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.10, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Genocea Biosciences and its competitors. For the Biotechnology industry, the median Days Payable is 113.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genocea Biosciences's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genocea Biosciences stock overvalued right now?
Genocea Biosciences (LTS:0A51) has a current Days Payable of 0.00. The current Days Payable is 0.00. Genocea Biosciences' overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Genocea Biosciences (LTS:0A51), the current Days Payable is 0.00 as of Mar. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Genocea Biosciences Business Description

Address 100 Acorn Park Drive, Cambridge, MA, USA, 02140
Genocea Biosciences Inc is a USA-based biopharmaceutical company discovering and developing novel cancer immunotherapies using its proprietary ATLAS platform. The ATLAS platform can profile each patient's CD4+ and CD8+ T cell immune responses to every potential target or antigen identified by next-generation sequencing of that patient's tumor. ATLAS zeroes in on both antigens that activate anti-tumor T cell responses and inhibitory antigens, or Inhibigens , that drive pro-tumor immune responses.
16GF Score

Get the complete analysis for LTS:0A51

Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price